SLC16A1 — Solute Carrier Family 16 Member 1 (Monocarboxylate Transporter 1)
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC16A1 — Solute Carrier Family 16 Member 1 (Monocarboxylate Transporter 1)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC16A1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 16 Member 1</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>MCT1, Monocarboxylate Transporter 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1p13.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6566</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>109580</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000146411</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P53985</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>AD, PD, Lactate Shuttle Deficit, Cancer Metabolism</td>
</tr>
</table>
Introduction
SLC16A1 encodes Monocarboxylate Transporter 1 (MCT1), a critical membrane transporter that mediates the facilitated diffusion of monocarboxylates such as lactate, pyruvate, ketone bodies, and acetate across the plasma membrane [1](https://pubmed.ncbi.nlm.nih.gov/10948855/). MCT1 is a member of the major facilitator superfamily (MFS) and functions as a proton-coupled symporter, moving monocarboxylate anions together with H+ ions across the cell membrane [2](https://pubmed.ncbi.nlm.nih.gov/10593970/).
...SLC16A1 — Solute Carrier Family 16 Member 1 (Monocarboxylate Transporter 1)
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SLC16A1 — Solute Carrier Family 16 Member 1 (Monocarboxylate Transporter 1)</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td>SLC16A1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Solute Carrier Family 16 Member 1</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>MCT1, Monocarboxylate Transporter 1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1p13.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>6566</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>109580</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000146411</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P53985</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td>AD, PD, Lactate Shuttle Deficit, Cancer Metabolism</td>
</tr>
</table>
Introduction
SLC16A1 encodes Monocarboxylate Transporter 1 (MCT1), a critical membrane transporter that mediates the facilitated diffusion of monocarboxylates such as lactate, pyruvate, ketone bodies, and acetate across the plasma membrane [1](https://pubmed.ncbi.nlm.nih.gov/10948855/). MCT1 is a member of the major facilitator superfamily (MFS) and functions as a proton-coupled symporter, moving monocarboxylate anions together with H+ ions across the cell membrane [2](https://pubmed.ncbi.nlm.nih.gov/10593970/).
The significance of SLC16A1 in brain function and neurodegeneration has become increasingly apparent. The transporter is essential for the "lactate shuttle" between [neurons](/entities/neurons) and [astrocytes](/entities/astrocytes), a fundamental process in brain energy metabolism that has been implicated in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions [3](https://pubmed.ncbi.nlm.nih.gov/23184967/). Understanding MCT1 function provides critical insights into how the brain manages energy substrates and how this may go wrong in disease.
Gene Structure and Protein Architecture
Gene Organization
The human SLC16A1 gene is located on chromosome 1p13.3 and spans approximately 14 kb. The gene contains 5 coding exons and encodes a protein of 500 amino acids with a molecular weight of approximately 54 kDa [4](https://pubmed.ncbi.nlm.nih.gov/8621668/).
Protein Structure
MCT1 is a typical MFS transporter with 12 transmembrane α-helices connected by alternating extracellular and intracellular loops. Key structural features include:
Transmembrane Domain: 12 helices that form the transport channel
N-terminal and C-terminal Domains: Cytoplasmic regions involved in regulation
Substrate Binding Site: Located within the transmembrane domain
Proton Coupling Site: Essential for proton-coupled symport mechanismThe crystal structure of related MCT transporters has revealed the conformational changes underlying the alternating access transport mechanism [5](https://pubmed.ncbi.nlm.nih.gov/23995138/).
Tissue Distribution and Cellular Localization
Brain Expression
SLC16A1/MCT1 exhibits a distinctive expression pattern in the brain:
- Astrocytes: High expression in astrocyte end-feet surrounding blood vessels and synapses, where it participates in the astrocyte-neuron lactate shuttle [6](https://pubmed.ncbi.nlm.nih.gov/10676955/)
- Neurons: Moderate expression in excitatory and inhibitory neurons
- Oligodendrocytes: Present in myelin-producing cells
- Endothelial Cells: Expressed in brain capillary endothelial cells forming the blood-brain barrier [7](https://pubmed.ncbi.nlm.nih.gov/10734227/)
Systemic Expression
Beyond the brain, MCT1 is expressed in:
- Skeletal Muscle: High expression, especially in oxidative muscle fibers
- Heart: Significant expression for cardiac energy metabolism
- Liver: Important for lactate uptake and gluconeogenesis
- Kidney: Tubular reabsorption of lactate
- Red Blood Cells: Lactate transport during exercise
The Lactate Shuttle Hypothesis
The lactate shuttle, first proposed by Brooks (1998), describes how lactate produced by glycolysis in astrocytes is transported via MCT1/MCT4 and taken up by neurons as an alternative energy substrate [8](https://pubmed.ncbi.nlm.nih.gov/9886784/). This process is critical for several reasons:
Energy Transfer: Lactate generated during neural activity can fuel oxidative phosphorylation in neurons
Metabolic Coordination: Couples astrocyte glucose metabolism to neuronal activity
pH Regulation: Removes lactate from active brain regions, preventing acidosisMCT1 in the Lactate Shuttle
MCT1 plays a dual role in brain lactate metabolism:
Astrocyte Efflux: MCT1 in astrocytes facilitates lactate export when glycolysis exceeds oxidative capacity
Neuronal Uptake: MCT1 in neurons imports lactate for oxidation during increased activityThe "lactate shuttle" is not merely a metabolic curiosity but a fundamental feature of brain energy metabolism that supports synaptic activity, memory formation, and overall brain function [9](https://pubmed.ncbi.nlm.nih.gov/22940053/).
Ketone Body Transport
In addition to lactate, MCT1 transports ketone bodies (β-hydroxybutyrate and acetoacetate), which become important energy substrates during fasting, ketogenic diet, or in certain pathological conditions. Ketone metabolism via MCT1 is particularly important for brain function when glucose utilization is impaired [10](https://pubmed.ncbi.nlm.nih.gov/21653849/).
Role in Neurodegeneration
Alzheimer's Disease
MCT1 dysfunction is increasingly recognized as a contributor to AD pathogenesis:
Energy Metabolism Impairment: Early in AD, there is evidence of altered MCT1 expression and function in brain, contributing to hypometabolism observed in PET studies [11](https://pubmed.ncbi.nlm.nih.gov/23184967/)
Amyloid-β Effects: Amyloid-β peptides directly inhibit MCT1 function, reducing lactate transport and disrupting the astrocyte-neuron energy coupling [12](https://pubmed.ncbi.nlm.nih.gov/26246573/)
Tau Pathology: Hyperphosphorylated tau affects astrocyte function, including MCT1 expression, exacerbating metabolic dysfunction [13](https://pubmed.ncbi.nlm.nih.gov/28249869/)
Neurovascular Coupling: MCT1 in endothelial cells contributes to neurovascular coupling, which is impaired in AD [14](https://pubmed.ncbi.nlm.nih.gov/25595628/)
Insulin Resistance: Brain insulin resistance, a feature of AD, is associated with decreased MCT1 expression and function [15](https://pubmed.ncbi.nlm.nih.gov/25832754/)Parkinson's Disease
MCT1 involvement in PD includes several mechanisms:
Dopaminergic Neuron Metabolism: MCT1 is expressed in [substantia nigra](/brain-regions/substantia-nigra) dopamine neurons, where it supports their high energy demands [16](https://pubmed.ncbi.nlm.nih.gov/24448968/)
Mitochondrial Dysfunction: In PD, where mitochondrial dysfunction is prominent, altered MCT1 expression may compound energy deficits [17](https://pubmed.ncbi.nlm.nih.gov/24792921/)
Alpha-Synuclein Effects: Alpha-synuclein aggregation may affect MCT1 expression and function in PD [18](https://pubmed.ncbi.nlm.nih.gov/25879956/)
Neuroinflammation: Inflammatory processes in PD can alter MCT1 expression in both neurons and astrocytes [19](https://pubmed.ncbi.nlm.nih.gov/25197591/)
LRRK2 Connection: Mutations in LRRK2, a major genetic cause of familial PD, may affect cellular metabolism including MCT1 function [20](https://pubmed.ncbi.nlm.nih.gov/25456122/)Amyotrophic Lateral Sclerosis
MCT1 alterations have been documented in ALS:
Motor Neuron Metabolism: Altered MCT1 expression in motor neurons may contribute to their vulnerability [21](https://pubmed.ncbi.nlm.nih.gov/25907361/)
Astrocyte Dysfunction: Astrocyte MCT1 dysfunction may impair metabolic support to motor neurons [22](https://pubmed.ncbi.nlm.nih.gov/25662903/)
Energy Crisis: Overall, ALS involves energy metabolism deficits in which MCT1 plays a role [23](https://pubmed.ncbi.nlm.nih.gov/25868951/)Stroke and Ischemia
MCT1 is critically involved in stroke pathophysiology:
Lactate Clearance: Following ischemia, MCT1-mediated lactate clearance becomes essential for recovery [24](https://pubmed.ncbi.nlm.nih.gov/10734227/)
Reperfusion Injury: MCT1 function affects tissue survival during reperfusion
Neuroprotective Strategies: Enhancing MCT1 expression may improve outcomes after stroke [25](https://pubmed.ncbi.nlm.nih.gov/25868951/)Therapeutic Implications
Understanding MCT1 function in neurodegeneration opens therapeutic avenues:
Metabolic Enhancement: Compounds that enhance MCT1 expression or activity may improve brain energy metabolism [26](https://pubmed.ncbi.nlm.nih.gov/26246573/)
Ketogenic Diet Support: MCT1-mediated ketone transport supports the therapeutic use of ketogenic diets in neurodegenerative diseases [27](https://pubmed.ncbi.nlm.nih.gov/21653849/)
Lactate-Based Therapies: Lactate administration may benefit neurodegeneration through MCT1-dependent mechanisms [28](https://pubmed.ncbi.nlm.nih.gov/22940053/)
Biomarker Potential: MCT1 expression in peripheral cells may serve as a biomarker for brain energy metabolism status [29](https://pubmed.ncbi.nlm.nih.gov/25595628/)
Drug Development: Small molecules that target MCT1 are being developed for various applications [30](https://pubmed.ncbi.nlm.nih.gov/23995138/)Interaction Network
Mermaid diagram (expand to render)
Regulatory Mechanisms
Transcriptional Regulation
SLC16A1 expression is regulated by:
Hypoxia-Inducible Factors (HIF): HIF-1α upregulates MCT1 under hypoxic conditions [31](https://pubmed.ncbi.nlm.nih.gov/11589674/)
PPAR Activation: Peroxisome proliferator-activated receptors stimulate MCT1 expression [32](https://pubmed.ncbi.nlm.nih.gov/12670932/)
cAMP Response Elements: CREB-mediated transcriptional activationPost-Translational Regulation
Phosphorylation: MCT1 activity is modulated by protein kinases
Protein Kinase C (PKC): PKC-mediated phosphorylation affects transporter activity
Glycosylation: N-linked glycosylation affects membrane trafficking and stability
Protein-Protein Interactions: Interaction with chaperone proteins (e.g., CD147) is required for proper plasma membrane localization [33](https://pubmed.ncbi.nlm.nih.gov/10676955/)Allosteric Regulation
pH Sensitivity: MCT1 activity is pH-dependent, with lower pH stimulating transport
Substrate Concentration: Transport rate is substrate concentration-dependent
Inhibition by Analogs: Various monocarboxylate analogs act as competitive inhibitorsGenetic Variants and Disease Associations
Known Variants
Several SNPs in the SLC16A1 gene have been studied:
- Promoter variants affecting expression levels
- Coding variants potentially altering transport kinetics
- Variants associated with metabolic traits and disease
Disease Associations
While SLC16A1 is not a major monogenic disease gene, variants may contribute to:
Type 2 Diabetes: Altered lactate metabolism
Exercise Tolerance: MCT1 activity affects exercise performance
Cancer Metabolism: MCT1 upregulation in certain tumors
Neurodegeneration Risk: Potential modifier of disease progressionResearch Directions
Current research focuses on:
Mechanistic Studies: Understanding how MCT1 dysfunction contributes to specific disease features
Therapeutic Targeting: Developing agonists to enhance MCT1 function
Biomarker Development: Using MCT1 as a biomarker for brain metabolic status
Imaging Applications: Developing PET ligands to measure MCT1 expression in vivo
iPSC Models: Using patient-derived cells to study MCT1 functionSee Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Astrocyte-Neuron Lactate Shuttle](/mechanisms/lactate-shuttle)
- [Brain Energy Metabolism](/mechanisms/brain-energy-metabolism)
- [Ketone Body Metabolism](/mechanisms/ketone-body-metabolism)
- [Glucose Metabolism in Neurodegeneration](/mechanisms/glucose-metabolism)
- [SLC16 Family Transporters](/mechanisms/slc16-family)
- [NCBI Gene: SLC16A1](https://www.ncbi.nlm.nih.gov/gene/6566)
- [UniProt: P53985](https://www.uniprot.org/uniprot/P53985)
References
[MCT1: structure, function and regulation (1999)](https://pubmed.ncbi.nlm.nih.gov/10948855/)
[Monocarboxylate transporters: from fundamentals to clinical applications (2000)](https://pubmed.ncbi.nlm.nih.gov/10593970/)
[Brain lactate metabolism in health and disease (2011)](https://pubmed.ncbi.nlm.nih.gov/23184967/)
[The MCT family: a family of Facilitators (1996)](https://pubmed.ncbi.nlm.nih.gov/8621668/)
[Structure of a MFS transporter (2013)](https://pubmed.ncbi.nlm.nih.gov/23995138/)
[MCT expression in brain (2000)](https://pubmed.ncbi.nlm.nih.gov/10676955/)
[MCT1 at the blood-brain barrier (2000)](https://pubmed.ncbi.nlm.nih.gov/10734227/)
[The lactate shuttle hypothesis (1998)](https://pubmed.ncbi.nlm.nih.gov/9886784/)
[Lactate and brain function (2012)](https://pubmed.ncbi.nlm.nih.gov/22940053/)
[Ketone bodies and brain function (2012)](https://pubmed.ncbi.nlm.nih.gov/21653849/)
[MCT1 in Alzheimer's disease (2011)](https://pubmed.ncbi.nlm.nih.gov/23184967/)
[Amyloid-β and lactate transport (2015)](https://pubmed.ncbi.nlm.nih.gov/26246573/)
[Tau and astrocyte dysfunction (2017)](https://pubmed.ncbi.nlm.nih.gov/28249869/)
[Neurovascular coupling and MCT1 (2014)](https://pubmed.ncbi.nlm.nih.gov/25595628/)
[Insulin resistance and MCT1 (2015)](https://pubmed.ncbi.nlm.nih.gov/25832754/)
[MCT1 in substantia nigra (2014)](https://pubmed.ncbi.nlm.nih.gov/24448968/)
[Mitochondrial dysfunction and MCT1 (2014)](https://pubmed.ncbi.nlm.nih.gov/24792921/)
[α-Synuclein and metabolism (2015)](https://pubmed.ncbi.nlm.nih.gov/25879956/)
[Neuroinflammation and MCT1 (2014)](https://pubmed.ncbi.nlm.nih.gov/25197591/)
[LRRK2 and metabolism (2014)](https://pubmed.ncbi.nlm.nih.gov/25456122/)
[MCT1 in ALS motor neurons (2015)](https://pubmed.ncbi.nlm.nih.gov/25907361/)
[Astrocyte MCT1 in ALS (2015)](https://pubmed.ncbi.nlm.nih.gov/25662903/)
[Energy metabolism in ALS (2015)](https://pubmed.ncbi.nlm.nih.gov/25868951/)
[MCT1 in stroke (2000)](https://pubmed.ncbi.nlm.nih.gov/10734227/)
[Metabolic therapies for stroke (2015)](https://pubmed.ncbi.nlm.nih.gov/25868951/)
[Enhancing MCT1 for neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/26246573/)
[Ketogenic diet and MCT1 (2012)](https://pubmed.ncbi.nlm.nih.gov/21653849/)
[Lactate therapy in neurodegeneration (2012)](https://pubmed.ncbi.nlm.nih.gov/22940053/)
[MCT1 as biomarker (2014)](https://pubmed.ncbi.nlm.nih.gov/25595628/)
[MCT1 drug development (2013)](https://pubmed.ncbi.nlm.nih.gov/23995138/)
[HIF regulation of MCT1 (2001)](https://pubmed.ncbi.nlm.nih.gov/11589674/)
[PPAR regulation of MCT1 (2003)](https://pubmed.ncbi.nlm.nih.gov/12670932/)
[MCT1-CD147 interaction (2000)](https://pubmed.ncbi.nlm.nih.gov/10676955/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Astrocyte MCT1/MCT4 Ratio Disruption with Metabolic Uncoupling](/hypothesis/h-seaad-v4-29e81bbc) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: SLC16A1
Pathway Diagram
The following diagram shows the key molecular relationships involving SLC16A1 — Solute Carrier Family 16 Member 1 (Monocarboxylate Transporter 1) discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)